As a targeted JAK1 inhibitor, and given its success in RA, Upadacitinib may represent an interesting therapeutic option for the inhibition of the STAT3 pathway in refractory LGLL patients [24,59]. This evidence concerns the gene STAT3 and T-cell large granular lymphocyte leukemia.